综上，我们同意提名王静女士、李训虎先生、汪东生先生为公司第三届董事会 独立董事候选人，并同意提交公司第二届董事会第十九次会议进行审议。 爱博诺德（北京）医疗科技股份有限公司董事会提名委员会 2025年5月23日 关于第三届董事会独立董事候选人的审查意见 爱博诺德（北京）医疗科技股份有限公司（以下简称"公司"）第二届董事会 任期即将届满。根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》《上市公司独立董事管理办法》及《爱博诺德（北京）医疗科技股 份有限公司章程》等有关规定，公司第二届董事会提名委员会对第三届董事会独立 董事候选人的任职资格进行了审核并发表审核意见如下： （一）经审阅公司第三届董事会独立董事候选人王静女士、李训虎先生、汪东 生先生的个人履历等相关资料，上述独立董事候选人未持有公司股份，与公司控股 股东、实际控制人、其他董事、高级管理人员以及持股5%以上股东不存在其他关联 关系，不存在《公司法》规定的不得担任公司的董事的情形；未被中国证监会采取 证券市场禁入措施；未被证券交易所公开认定为不适合担任上市公司董事；未受过 中国证监会行政处罚和证券交易所公开谴责或通报批评； ...

证券代码：688050 证券简称：爱博医疗 公告编号：2025-038 爱博诺德（北京）医疗科技股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 股东大会召开日期：2025年6月19日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 网络投票起止时间：自2025 年 6 月 19 日 至2025 年 6 月 19 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互 联网投票平台的投票时间为股东大会召开当日的 9:15 ...

爱博诺德（北京）医疗科技股份有限公司监事会 关于公司 2021 年限制性股票激励计划首次授予部分第四个归属 期及预留授予部分第三个归属期归属名单的核查意见 2025 年 5 月 29 日 1 监事会认为，首次授予 71 名激励对象及预留授予 6 名激励对象符合《公司 法》《证券法》等法律、法规、规范性文件以及《公司章程》规定的任职资格， 符合《管理办法》《上市规则》等法律、法规和规范性文件规定的激励对象条件， 符合公司《2021 年限制性股票激励计划》及其摘要规定的激励对象范围，其作 为公司本次激励计划激励对象的主体资格合法、有效，激励对象获授限制性股票 的归属条件已成就。 综上所述，监事会同意公司 2021 年限制性股票激励计划首次授予部分第四 个归属期及预留授予部分第三个归属期归属名单。 爱博诺德（北京）医疗科技股份有限公司监事会 爱博诺德（北京）医疗科技股份有限公司（以下简称"公司"）监事会依据 《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》 （以下简称"《证券法》"）、《上市公司股权激励管理办法》（以下简称"《管理办 法》"）、《上海证券交易所科创板股票上市规则》（以下简 ...

证券代码：688050 证券简称：爱博医疗 公告编号：2025-029 爱博诺德（北京）医疗科技股份有限公司 第二届监事会第十六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 爱博诺德（北京）医疗科技股份有限公司（以下简称"公司"）第二届监事 会第十六次会议通知及相关材料于 2025 年 5 月 23 日以电子邮件的方式发出。会 议于 2025 年 5 月 29 日在公司会议室以现场与通讯相结合方式召开，本次会议由 监事会主席王丹璇女士召集并主持，应出席的监事 3 人，实际出席的监事 3 人。 本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法律、法规、 规章、规范性文件和《公司章程》等有关规定，会议形成的决议合法、有效。经 与会监事认真讨论，审议通过如下事项： 一、审议并通过《关于 2024 年年度利润分配方案的议案》 经与会监事认真审议，监事会认为：公司 2024 年年度利润分配方案充分考虑 了公司盈利情况、现金流状态及资金需求计划，结合了当前发展阶段、长远发展 规则及股东合理回报规划等各种 ...

证券代码：688050 证券简称：爱博医疗 公告编号：2025-028 爱博诺德（北京）医疗科技股份有限公司 第二届董事会第十九次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 爱博诺德（北京）医疗科技股份有限公司（以下简称"公司"）第二届董事 会第十九次会议通知及相关材料于 2025 年 5 月 23 日以电子邮件方式发出。会议 于 2025 年 5 月 29 日在公司会议室以现场与通讯相结合方式召开，本次会议由董 事长解江冰先生召集并主持，应出席参加表决的董事 9 人，实际出席参加表决的 董事 9 人，全体监事和高级管理人员列席了会议。本次会议的召集、召开和表决 程序符合《中华人民共和国公司法》等法律、法规、规章、规范性文件和《公司 章程》等有关规定，会议形成的决议合法、有效。经与会董事认真讨论，审议通 过如下事项： 1 期三年。 本议案已经董事会提名委员会审议通过。 表决结果：同意 9 票，反对 0 票，弃权 0 票。 一、审议并通过《关于董事会换届选举暨提名第三届董事会非独立董事的议 案》 经与会董事 ...

证券代码：688050 证券简称：爱博医疗 公告编号：2025-032 爱博诺德（北京）医疗科技股份有限公司 2024 年年度利润分配方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 每股分配比例：每 10 股派发现金红利 3.50 元（含税），不进行资本公积 转增股本，亦不派送红股。 ● 本次利润分配以实施权益分派股权登记日登记的总股本扣除公司回购专用 证券账户中的股份数量为基数，具体日期将在权益分派实施公告中明确。 ● 在实施权益分派的股权登记日前，爱博诺德（北京）医疗科技股份有限公 司（以下简称"公司"）总股本发生变动的，拟维持每股分配比例不变，相应调 整现金分红总额，并将另行公告具体调整情况。 ● 本次利润分配方案不触及《上海证券交易所科创板股票上市规则》第 12.9.1 条第一款第（八）项规定的可能被实施其他风险警示的情形。 ● 本年度现金分红比例低于归属于上市公司股东净利润的 30%，主要因为公 司隐形眼镜业务处于快速扩张阶段，资金需求有所增加，且公司计划加大海外市 场开拓及持续探 ...

Key Insights - The report highlights the macroeconomic environment, indicating a weakening policy support effect on bonds, while still suggesting that bonds have underlying support [6] - The report emphasizes the growth potential of the tea beverage industry, particularly focusing on the performance and expansion of the company, Mixue Group, which is positioned as a leader in the ready-to-drink tea market [7][8] - The report discusses the financial performance of various companies, including Mylab Biotech and Aibo Medical, noting their strategic adjustments and growth trajectories [11][16] Group 1: Mixue Group - Mixue Group is the largest ready-to-drink tea company globally, with a store count reaching 46,479 by the end of 2024, and a revenue of 24.83 billion RMB, reflecting a 22.3% year-on-year growth [7] - The company has a strong focus on cost-effective products priced between 2-8 RMB, with a significant portion of its stores located in lower-tier cities, accounting for 57.4% of its total store count [7] - The revenue composition for 2024 shows that product sales, equipment sales, and franchise services contribute 94.5%, 3.0%, and 2.5% respectively, with product sales being the core revenue driver [7] Group 2: Industry Growth - The ready-to-drink tea market is projected to reach approximately 310.9 billion RMB by 2025, with a compound annual growth rate (CAGR) of about 19.7% from 2023 to 2028 [8] - Mixue holds a market share of 20.2% in the ready-to-drink tea segment, leading the competition [8] - The report notes that the Southeast Asian market is a primary target for Mixue's international expansion, where it has achieved a market share of approximately 19.5% [8] Group 3: Mylab Biotech - Mylab Biotech reported a revenue of 2.549 billion RMB in 2024, a decline of 11.98%, with a net profit of 127 million RMB, down 59.44% [11] - The company is undergoing a strategic transition, focusing on increasing its share of self-developed products, which now account for 75.07% of its revenue [11] - The report indicates that Mylab's self-developed products are expected to grow, with a focus on smart laboratory solutions [12] Group 4: Aibo Medical - Aibo Medical achieved a revenue of 1.41 billion RMB in 2024, marking a 48.24% increase, with a net profit of 388 million RMB, up 27.77% [16] - The company is in the growth phase for its vision care business, with the first domestically produced intraocular lens approved for sale [16] - The report highlights the potential for Aibo's products to capture market share, particularly in the context of increasing demand for vision correction solutions [17]

Investment Rating - The investment rating for the company is "Outperform the Market" [5][4][27] Core Viewpoints - The vision care business is in a nurturing phase, with the first domestically produced intraocular lens, Longjing, approved for market launch [3][4] - Revenue is expected to grow rapidly, with projected revenue of 1.41 billion in 2024 (+48.24%) and a net profit of 388 million (+27.77%) [9][4] - The company is focusing on expanding its product lines, particularly in contact lenses and intraocular lenses, to enhance its market position [2][4] Revenue and Profitability - In 2024, the company achieved revenue of 1.41 billion (+48.24%) and a net profit of 388 million (+27.77%), with Q4 revenue at 335 million (+18.26%) and net profit at 71 million (+36.15%) [9][4] - The revenue from artificial lenses reached 588 million (+17.66%), with a significant volume increase of 44.93% [2][4] - The gross profit margin for 2024 was 66.23%, a decrease of 9.78 percentage points, primarily due to the increased revenue share from lower-margin contact lens products [3][4] Business Segments - The artificial lens segment is showing strong growth, while the contact lens segment has seen a revenue increase of 211.84% to 426 million, with a volume increase of 241.11% [2][17] - The company is actively diversifying its product offerings in myopia control, leading to a 20.79% increase in revenue from related products [2][4] Financial Forecasts - The company has revised its profit forecasts for 2025-2026, now expecting net profits of 469 million and 578 million, respectively, with a new forecast for 2027 at 717 million [4][27] - The projected net profit growth rates for 2025-2027 are 20.7%, 23.4%, and 23.9% respectively [4][27] Research and Development - The company maintains a high level of R&D investment, with 160 million allocated in 2024, representing 11.33% of revenue [23][4] - The successful approval of the Longjing intraocular lens fills a significant gap in the domestic market, showcasing the company's innovation capabilities [3][4]

Core Insights - The company achieved a revenue of 1.41 billion (+48.24%) and a net profit of 388 million (+27.77%) in 2024, with the vision care business still in the cultivation phase [1] - The artificial crystal sales volume offset the impact of price reductions from centralized procurement, with the vision care business revenue proportion increasing to 30% [2] - The gross profit margin for 2024 was 66.23% (-9.78pp), primarily affected by the increased revenue share from lower-margin contact lens products [3] Group 1: Financial Performance - In Q4 2024, the company reported a revenue of 335 million (+18.26%) and a net profit of 71 million (+36.15%) [1] - For Q1 2025, the company achieved a revenue of 357 million (+15.07%) but experienced a decline in net profit to 93 million (-10.05%) due to multiple factors [1] - The artificial crystal revenue was 588 million (+17.66%) with a sales volume increase of 44.93% [2] Group 2: Product Performance - The "Puno Tong" orthokeratology lens generated revenue of 236 million (+8.03%) with a sales volume growth of 2.40% [2] - Contact lens revenue surged to 426 million (+211.84%) with a sales volume increase of 241.11%, driven by increased production capacity and market investment [2] - The first domestic intraocular lens, "Longjing," was approved for market release in early 2025, filling a gap in domestic intraocular lens products [3] Group 3: Cost and Profitability Metrics - The gross profit margin decreased due to the higher revenue share from lower-margin contact lens products [3] - The net profit margin for 2024 was 27.45% (-2.62pp), with Q1 2025 showing a slight improvement to 25.14% [3] - The company maintains a strong pipeline of innovative projects, including the recently approved artificial crystalline lens [3]

Investment Rating - The investment rating for the company is "Outperform the Market" [5] Core Views - The vision care business is in a nurturing phase, with the first domestically produced intraocular lens, Longjing, approved for market launch [3][4] - Revenue is expected to grow rapidly, with projected revenue of 1.41 billion in 2024 (+48.24%) and a net profit of 388 million (+27.77%) [9][4] - The company is focusing on expanding its product lines, particularly in contact lenses and intraocular lenses, to enhance its market position [4][17] Revenue and Profitability - In 2024, the company achieved revenue of 1.41 billion (+48.24%) and a net profit of 388 million (+27.77%), with Q4 2024 revenue at 335 million (+18.26%) and net profit at 71 million (+36.15%) [9][4] - The revenue from artificial lenses reached 588 million (+17.66%), with a volume increase of 44.93% [2][16] - The gross profit margin for 2024 was 66.23%, down 9.78 percentage points, primarily due to the increased revenue share from lower-margin contact lens products [3][18] Business Segments - The artificial lens segment is growing, with high-end products like "All-View" multifocal lenses seeing rapid growth, although their market share remains low [2][16] - The revenue from contact lenses surged to 426 million (+211.84%), with a volume increase of 241.11%, driven by increased production capacity and market investment [17][2] - The company is actively diversifying its product offerings in myopia control, leading to a 20.79% increase in revenue from related products [2][16] Financial Forecasts - The company has revised its profit forecasts for 2025-2026, now expecting net profits of 469 million and 578 million, respectively, with a new forecast for 2027 at 717 million [4][28] - The projected net profit growth rates for 2025-2027 are 20.7%, 23.4%, and 23.9% respectively [4][28] - The current stock price corresponds to a PE ratio of 30.7 for 2025, 24.8 for 2026, and 20.1 for 2027 [4][28] Research and Development - The company maintains a high level of R&D investment, with 160 million allocated in 2024, representing 11.33% of revenue [23][4] - The first domestically produced intraocular lens, Longjing, was approved for market launch in early 2025, filling a significant gap in the domestic market [3][23] - The company has a rich pipeline of projects, including various advanced intraocular lenses and contact lenses, indicating strong future growth potential [24][23]